We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy


DETECTION of genetic alterations in cancer
Molecular biology laboratories use a number of different methods to investigate cancer genetics and detect a range of genetic alterations that may be potential therapeutic targets.

Molecular analyses involve an evaluation by an expert pathologist who selects the tumor area to be tested. The three main types of tests are: DNA analysis, messenger mRNA expression analysis, and protein expression. Although these are all carried out in tumor tissue or ‘liquid biopsies’, their clinical significance may vary. For example, EGFR mutations predict good sensitivity to tyrosine kinase inhibitors in lung cancer, whereas expression levels of messenger RNA or proteins do not have any predictive value for this type of cancer.

In solid tumors, most tests are performed in formalin-fixed, paraffin-embedded tumor tissue. However, some patients do not have sufficient tumor tissue available to perform vital genetic analyses. Therefore, we are leaders in the field of non-invasive diagnostic tests using alternative biosources such as cerebrospinal fluid or serum, plasma and platelets from blood samples to detect certain mutations.

For a complete list of the molecular and pathological diagnostic tests we perform in the Molecular Oncology and Pathology Laboratory, as well as the procedure for sending samples, please see our Test Catalogue.

Please note that all tests must be requested by a medical professional.